We previously described the development of nonproteinuric diabetic nephropathy (NPDN) in the Cohen diabetic rat (CDs), a model that simulates Type 2 diabetes in humans. Using linkage analysis in an F2 cross, we currently set out to investigate the mechanisms underlying NPDN. We crossbred between CDs and SBN/y, a nondiabetic rat strain, generated F1 and F2 progenies, fed them diabetogenic diet that elicits diabetes and NPDN in CDs but not in SBN/y, and determined metabolic and renal phenotypes. Over 5 mo, ϳ75% of F2 developed a diabetic phenotype. In parallel, a nephropathy developed in F2, with glomerular filtration rate (GFR) declining in ϳ25% and, unexpectedly, significant proteinuria appearing in ϳ75%. We scanned the F2 genome with microsatellite markers and used linkage analysis to identify quantitative trait loci (QTLs). We detected diabetes-related QTLs on RNO4 and 13. We also detected two QTLs for the decline in GFR on RNO4 and 13 and another QTL for proteinuria on RNO13. The metabolic and renal-related QTLs overlapped. These results suggest that the mechanisms underlying the nephropathy in F2 are related to genes that map to RNO4 and 13, as well as a common genetic background for the development of diabetes and the renal disease. Our findings further indicate that proteinuria is inhibited in parental diabetic CDs, thus accounting for the nonproteinuric phenotype, but "unmasked" in diabetic F2 whose genome has been modified. Identifying the nature of the factor inhibiting proteinuria in diabetic CDs but not in F2 may provide a clue to treatment and prevention of proteinuria in diabetes.
Type 2 diabetes; nephropathy; quantitative trait loci; linkage analysis; genes PROTEINURIA HAS BEEN TRADITIONALLY viewed as a surrogate for diabetic nephropathy in both humans and experimental models. The absence of proteinuria in the diabetic patient is generally considered a reassuring sign, signifying the absence of nephropathy. Moreover, when renal failure develops in a diabetic patient without proteinuria, the cause of kidney dysfunction is usually attributed to other nondiabetic kidney disease. The reassurance derived from the absence of proteinuria may, however, be deceptive, as several reports over the past decade have suggested that impaired glomerular filtration can also occur in the diabetic patient without the appearance of proteinuria, as direct complication of longstanding diabetes (5, (7) (8) (9) (10) (11) . The mechanisms underlying this not-uncommon nonproteinuric type of diabetic nephropathy (NPDN) are poorly understood, and no therapeutic or preventive measures are currently proposed.
We have been studying the pathophysiology of nephropathy in the Cohen diabetic rat (CDs), an experimental model of Type 2 diabetes (6, 12, 13) . While investigating the renal phenotype, we previously found and reported that the CDs strain develops over several months a progressive decline in glomerular filtration, without the appearance of proteinuria (13) . CDs thus appears to represent a model of NPDN in the diabetic rat that is unique of its kind (4, 6, 13) .
In the current study, we set out to investigate the pathophysiology of the nonproteinuric type of nephropathy in the Cohen rat by a genomic approach. The results of our study provide novel information that may shed light on the differences between the proteinuric and nonproteinuric types of diabetic nephropathy in humans.
RESEARCH DESIGN AND METHODS

Animals
Our experimental model was the CDs diabetes-prone rat strain (12) , which, as we have previously shown, develops diabetes as well as NPDN when fed a diabetogenic diet (DD) (13) . As contrasting strain, we chose the SBN/y strain, which is not diabetes prone and which does not develop nephropathy (15) . We obtained both strains from the Israeli Rat Genome Center at the Barzilai Medical Center Campus of the Ben-Gurion University in Ashkelon, Israel (http://www.irgc.co.il).
The study was reviewed and approved by the Institutional Animal Usage Review Board. We housed the animals in accordance with institutional regulations, the principles of laboratory animal care (National Institutes of Health publication no. 85-23, revised 1985) , and the guidelines of the American Physiological Society for the care of laboratory animals. We maintained climate-controlled conditions, setting the temperature at 22-24°C and regularly timed diurnal light cycles.
We weaned the animals at age 1 mo and provided them for 2 wk with standard rat chow [regular diet (RD)] containing 0.25% NaCl (Koffolk, Tel-Aviv, Israel) and tap water ad libitum. At age 6 wk, the animals were switched to DD for the remainder of the study period. We custom-prepared the DD, as previously described (12) . the phenotype of parental SBN/y and CDs for reference and of F1 by a protocol that was identical to that applied in F2. Because of the magnitude of the study, we limited the study to the male sex.
While studying the resulting cross, we found that certain phenotypes in F2, namely kidney size, kidney mass, and urinary protein excretion, were distinctly different from those that we had found in both parental strains. We hypothesized that these findings in F2 were related to DD and the development of diabetes. To test this hypothesis, we repeated the F2 cross and studied the F2 animals (n ϭ 109) after feeding with RD as opposed to DD, thereby controlling for the "diabetogenic" factor.
Phenotypes
Metabolic. To ascertain that the animals developed diabetes when fed DD, we performed an oral glucose tolerance test (OGTT) at 1, 2.5, and 4 mo after initiation of DD. We performed the OGTT after overnight fasting by measuring glucose levels in whole blood taken from the tip of the tail with a standard automated glucometer (Elite, Bayer). We then loaded the animals by gavage with glucose dissolved in distilled water (3.5 g glucose/kg body wt) and measured blood glucose levels after 15, 30, 60, 120, and 180 min. We calculated the area under the curve (AUC) of the glucose levels during the OGTT (AUC-OGTT) and used it as a quantitative estimate of the severity of diabetes
Renal. As surrogates of kidney function, we used plasma creatinine, creatinine clearance (CrCl), plasma urea levels, and 24 h urinary protein excretion. We determined kidney function every 2 wk over 5 consecutive months.
We determined plasma creatinine and urea in blood obtained from the tip of the tail with a Beckman auto-analyzer. We calculated CrCl, an approximation of glomerular filtration rate (GFR), by the standard clearance formula based on plasma and urinary creatinine levels and 24 h urine volume. To measure urine creatinine, we used the colorimetric Jaffe reaction in a microplate reader set at 492 nm and a standard curve. We collected urine over 24 h in metabolic cages. To determine the amount of protein excreted, we used the urinary protein concentration and 24 h urinary excretion rate. To measure urinary protein concentration, we used a turbometric reaction with sulfosalicylic acid, determining the optical density with a microplate reader set at 450 nm and a standard curve.
At the end of the study, we killed the animals, removed the kidneys, recorded their weight, and preserved them in formaldehyde. In representative cases, we studied the histology of the kidneys. For histological examination, we prepared paraffin blocks, cut 3 m thin slices, and stained them with hematoxylin and eosin, periodic acid-Schiff, Masson's trichrome, and oil red O.
Genotype
For genotype determination, we extracted genomic DNA from the liver by salt precipitation, followed by cleaning with phenol-chloroform (15) . We assessed DNA purity and quantity by spectrophotometry. We determined the genotype of each animal by PCR amplification of genomic DNA with marker (microsatellite) specific primers, as previously described (16) .
We scanned the entire rat genome for linkage with the respective phenotypes. We used microsatellite markers that we previously found to be polymorphic between CDs and SBN/y. We targeted markers spaced 10 -20 cM apart on each chromosome. When we detected a quantitative trait locus (QTL), we increased the density of the markers within that chromosome. The microsatellite markers were custom synthesized by Genosys (Sigma), with primer sequences provided by RGD (http://www.rgd.mcw.edu).
Statistics and Genomic Analyses
We provide the phenotypic data as means Ϯ standard error. We compared between groups using the Student's t-test or one-way analysis of variance (ANOVA) with post hoc least significant difference testing, as applicable, using PC-based Statistica software. For genomic analysis, we used linkage and cosegregation. We required both to yield significant results for definite QTL identification.
Linkage analysis. For linkage analysis, we used the MultiQTL software package, version 2.6 (http://www.multiqtl.com), as previously described (3, 14) . In brief, we initially screened the entire genome for genetic linkage by single trait analysis. We analyzed each time period (in months after initiation of DD) separately, testing simultaneously 116 measured or derived phenotypes. We determined statistical significance (P value) of individual QTLs by permutation testing. When significant, we proceeded with bootstrap analysis, which provided us with the power of QTL detection, the chromosomal position of the peak logarithm-of-the-odds score, the confidence intervals of the QTL span, and the percentage of the phenotypic variation accounted for by the QTL. When we detected linkage at consecutive time points for the same phenotype, we applied multienvironment analysis, which incorporates different time points after intervention (initiation of DD) as separate "environments." We utilized as default the unrestricted model but strove at each step of the analysis to fit the QTL to the simplest and statistically justified model (dominant, recessive, or additive effect).
Cosegregation analysis. We compared the phenotypic values in F2 of those animals with CDs and SBN/y alleles (SS -homozygous for CDs, NN -homozygous for SBN/y, and SN -heterozygous with one allele from CDs and the other from SBN/y) by ANOVA. This additional analysis allowed us to confirm independently the presence of the QTL and determine the effect of the genotype on the selected phenotype.
RESULTS
Metabolic Phenotype
The AUC-OGTT in CDs-DD at 1, 2.5, and 4 mo after the initiation of DD was elevated and higher than in SBN/y-DD, indicating the development of diabetes in CDs but not in 
Renal Phenotypes of First Cross
CrCl. Baseline CrCl at time 0 (age 7 wk) was low in all groups (Fig. 2, A and B) . In CDs-RD, SBN/y-DD, and SBN/ y-RD, CrCl gradually increased, achieving peak levels at 4 -5 mo. In contrast, CrCl peaked in CDs-DD at a low value at 1 mo, with no further rise thereafter. Consequently, as of the first month and until the end of the study, CDs-DD had significantly lower CrCl than the other groups. In F1-DD, the pattern was similar to CDs-RD, SBN/y-RD, and SBN/y-DD. In F2-DD, CrCl varied widely over the entire study period, with a significant number of animals exhibiting a low CrCl at 4.5-5 mo.
Plasma urea. Baseline urea was similar in all groups (Fig. 2 , C and D). In CDs-RD, SBN/y-RD, and SBN/y-DD, urea remained unchanged throughout the study period. In contrast, urea rose in CDs-DD as of month 2 and consequently was significantly higher than in the other groups from thereon and until the end of the study. In F1-DD, urea gradually increased over time, rendering the values at 4 and 5 mo intermediate between CDs-DD and the other groups. In F2-DD, urea levels varied widely over the 5 mo of follow up, with a significant number of animals exhibiting a gradual increase in levels after 2.5 mo. Urinary protein excretion. Protein excretion in CDs and SBN/y was negligible at baseline and remained Ͻ25 mg/24 h in both strains on either diet, indicating the absence of proteinuria in both parental strains on either DD or RD (Fig. 2, E and  F) . In F1-DD, urinary protein excretion generally remained low throughout the study period but in 2/7 animals, the levels of proteinuria gradually increased and at 5 mo were 76 and 62 mg/day. In F2-DD, significant proteinuria developed at 2.5 mo and markedly increasing thereafter in 109 animals, far beyond the protein excretion rate that we had found in the parental strains.
Kidney mass. After 5 mo of DD, the kidney mass of CDs-DD was twice that of CDs-RD and SBN/y-DD (Fig. 3) . In F1-DD, the kidney mass was intermediate between CDs-DD and SBN/y-DD. In F2-DD, the kidney mass was markedly elevated in a ϳ10% of animals, exceeding severalfold the mass in both parental strains fed DD for a similar period of time (image shown in Fig. 3 demonstrating a markedly enlarged kidney). The animals with the large kidneys had an elevated AUC during the OGTT, an increased plasma urea, low CrCl (similar to CDs-DD), as well as significant proteinuria.
Kidney histology. The histology of the kidneys by light microscopy in parental CDs and SBN/y after 5 mo feeding with DD was essentially normal, except for a variable increase in glomerular glycoprotein and collagen deposition in CDs-DD. In contrast, F2-DD kidneys demonstrated more remarkable changes, ranging from normal appearance, through focal and segmental glomerular changes, to generalized and diffuse glomerular and tubular changes. Glomerular changes consisted of mesangial matrix expansion, presence of numerous glomerular cells with foamy cytoplasm staining positive for oil-red O (neutral fat), and multiple capsule-tuftal adhesions. In some of these kidneys, foamy cells formed a glomerular crescent. Tubular changes consisted of extreme dilatation of the distal tubules with cyst formation, the presence of protein casts and calcifications in many tubules, and in one instance dilatation of the proximal tubules. The collecting tubules and the intrarenal vessels appeared normal. We examined by electron microscopy the kidneys of 5 F2. In 3/5, we did not find any glomerular changes and the thickness of the glomerular basement membrane was normal (206 -302 nm). In two kidneys, the mesangial matrix was expanded with electron dense deposits, the peripheral capillary basement membrane was thickened, measuring 367-512 nm, and the podocyte cytoplasm contained numerous lipid droplets corresponding to the oil-red O-positive foam cells. Representative images of the findings are provided in Fig. 4 .
Renal Phenotypes of Second (Repeat) Cross
CrCl, plasma urea, urinary protein excretion, and kidney mass in parental, F1, and F2 strains of the second cross after 5 mo feeding with RD are shown in Table 1 . F2-RD animals in this second cross did not exhibit the decline in CrCl, the rise in plasma urea, the level of proteinuria, or the increase in kidney mass that we had found in the first cross.
Genomic Analysis of the F2 Cross
We screened the entire rat genome in 166 male F2 rats for genetic linkage with the renal phenotypes of interest.
CrCl. At 5 mo DD, the time point at which we observed the most notable decline in glomerular filtration, we found two QTLs with significant linkage for CrCl, on RNO4 (Fig. 5A , Table 2 ) and RNO13 (Fig. 5B, Table 2 ) respectively. We confirmed the two QTLs by cosegregation analysis (Tables 3  and 4) , the CDs (SS) genotype being associated with lower CrCl than those with the SBN/y (NN) or heterozygote (NH) genotypes.
Plasma urea levels. We detected two QTLs for plasma urea with significant linkage from 1-3 mo DD on RNO4 (Fig. 5C , Table 2 ) and from 2-5 mo DD on RNO13 (Fig. 5D, Table 2 ). We confirmed both QTLs by cosegregation analysis, the SS genotype being associated with higher plasma urea levels than those with the NN or SN genotypes (Tables 3 and 4) .
Urinary protein excretion. We detected one QTL for proteinuria with linkage on RNO13 from 4 -5 mo DD (Fig. 5F , Table 2 ). We confirmed the QTL by cosegregation analysis, which indicates that the level of protein excretion by F2 animals with the SS genotype gradually increased, so that by 4 and 4.5 mo it was significantly higher than those with the NN and SN genotypes (Table 4) .
Kidney mass. We detected one QTL for kidney mass with linkage on RNO4 (Fig. 5E, Table 2 ). We confirmed the QTL by cosegregation analysis, the kidney weight in F2 with the SS genotype after 5 mo of DD averaging more than twice that of those with NN or NH genotypes (Table 3) .
DISCUSSION
We previously identified the CD rat as a model simulating NPDN and described the associated phenotype in depth (13) . In the current study, we initiated the investigation of the pathophysiology of this type of nephropathy with the genomic approach. The major novel finding in this study was the appearance As opposed to the 1st cross during which animals were fed diabetogenic diet (DD), in this cross animals were fed regular diet throughout the 5 mo experimental period. CDs, Cohen diabetic rat; CrCl, creatinine clearance.
in F1 and F2 of proteinuria, which is not part of the renal phenotype of the parental diabetic CDs strain (hence the term "nonproteinuric diabetic nephropathy"). The second novel finding was that the genes that are involved in this type of nephropathy map to genetic loci on rat chromosomes 4 and 13. Differences in the regulation of gene expression at these loci may underlie the differences between the nonproteinuric and proteinuric varieties of nephropathy in diabetes.
The appearance of proteinuria (defined as total protein excretion Ն30 mg/24 h) in F1 and F2 progenies of the cross, despite the total lack of proteinuria (Ͻ30 mg/24 h) in the parental CDs or SBN/y strains is, in our view, one of the most significant findings in this study. Even though we set out, upon initiation of the study, to investigate the genetic basis of a nonproteinuric type of diabetic nephropathy, it turned out that crossbreeding the diabetes-prone CDs with another nondiabetic SBN/y strain led the nonproteinuric type of nephropathy in the parental strains to evolve into a proteinuric type of nephropathy among F2. Because of the unexpected nature and unclear significance of the appearance of proteinuria in F2, we sought to ascertain whether the proteinuric phenotype was causally related to the DD and the development of diabetes. To resolve this issue, we carried out an additional set of experiments, repeating the F2 cross using a protocol that was identical to the one used in the first cross, with the exception that neither F1 nor F2 were fed DD but rather RD that does not elicit diabetes in the parental strains. None of the F1-RD or F2-RD animals in the repeat cross developed diabetes, proteinuria, a decreased CrCl, a rise in plasma urea, or an increase in kidney mass. The repeat cross thus indicates that the appearance of proteinuria and the decline in GFR in F2-DD in the first cross were indeed related to DD. Were these phenotypes also related to the development of diabetes? We analyzed the functional data to determine whether in F2-DD, proteinuria, the decline in GFR, and the increased renal mass correlated with the AUC during the OGTT, a surrogate of the metabolic diabetic phenotype. As shown in Fig. 6 , CrCl correlated inversely with AUC-OGTT, whereas plasma urea correlated positively with AUC-OGTT, suggesting that the more diabetic the animals were, the greater was the reduction in GFR. Kidney mass correlated positively with the AUC-OGTT as well, suggesting that the higher kidney mass was also associated with the development of diabetes. In contrast, we did not find a correlation between proteinuria and the AUC-OGTT. One possible explanation for this lack of correlation may be that in F2, we dissociated the genes responsible for diabetes and for proteinuria and that they are not identical. When we studied the individual animals in the F2 cohort, we found that most animals that developed proteinuria also had an elevated AUC-OGTT but that not all animals with an elevated AUC-OGTT developed proteinuria. Furthermore, we observed a decline in GFR in some, but not all of the proteinuric F2. Such findings are consistent with observations in human that not all diabetics develop proteinuria in the course of their metabolic disease, that the first expression of diabetic nephropathy is often proteinuria, and that a decline in GFR occurs at a later stage only in some of the diabetic subjects with proteinuria (1, 2) .
The appearance of proteinuria in 2/7 F1 and in many F2 animals, but not in the parental diabetic CDs strain, is perplexing. The only plausible explanation is that proteinuria is "masked" in the parental CDs strain by a genetic makeup that is "protective" of urinary protein leak. We speculate that in F1 and F2, "unmasking" occurred as result of mixing of the genomes of CDs and SBN/y, allowing proteinuria to develop as part of the nephropathy phenotype. The genomic factor that masks proteinuria in the parental CDs strain but not in F2 could be a protective gene or a "regulatory" factor, such as a microRNA, imprinting. or an epigenetic factor that may be unrelated to the development of diabetes per se and the identity of which remains to be determined. The appearance of proteinuria in ϳ75% and the lack of proteinuria in ϳ25% of F2 animals suggest that in the course of the F2 cross, we unmasked one dominant proteinuria-related gene. The mode of inheritance of the other renal phenotypes was variable; CrCl suggests a recessive pattern for F1 and F2, plasma urea a complex pattern for F1, and a dominant pattern for F2 and kidney mass involving a complex pattern for F1 and a recessive pattern in F2. The significance of these variable modes of inheritance for the different renal phenotypes is unclear at this stage, although it supports a polygenic multifactorial mode of transmission of the renal disease.
We pursued our investigation by seeking genomic loci that would account for the four major surrogates of the renal disease, CrCl, plasma urea, urinary protein excretion, and kidney mass. We succeeded in identifying QTLs on both RNO4 and RNO13 for CrCl and plasma urea. The QTLs for these two traits overlapped on both chromosomes, as might be expected, as both CrCl and plasma urea reflect glomerular Flanking markers, markers defining the 95% confidence interval of the quantitative trait locus (QTL); Max LOD, chromosomal position of maximal logarithm of the odds (LOD) score; POD, power of detection; Span, span of the QTL as defined by the 95% confidence interval; PVT, percent of the phenotypic variation to which the QTL contributes. filtration. For the development of proteinuria, we identified a QTL on RNO13 with a dominant mode of inheritance, and for kidney mass another QTL on RNO4, also with a dominant mode of inheritance. Interestingly enough, the QTL on RNO13 for proteinuria overlaps with that of CrCl and plasma urea on that same chromosome. Furthermore, the QTLs that we detected on both RNO4 and 13 overlap with the QTLs that have been assigned to the metabolic diabetic phenotype (unpublished observations). What is the significance of this overlap? Since the spans of the QTLs we currently identified are relatively large, we cannot infer from the overlap an identity between the QTLs. Even though it is attractive to speculate that similar genes account for the respective phenotypes, it is quite possible that different genes that cluster within a similar genomic region account for the respective traits. The large number of genes in the QTLs on RNO4 and RNO13 also prevents us from speculating at this stage on the identity of the genes responsible for the development of nephropathy. Suffice to hypothesize that either genes that are responsible for the development of diabetes in this model are also responsible for the development of nephropathy, or that genes responsible for the development of diabetes are in genomic proximity to those that account for the nephropathy we observed. We have previously identified several candidate genes for the development of diabetes on RNO4, and it remains for us to determine the possible role of these same genes in the development of the nephropathy in the CD rat. In addition, a confirmatory study is warranted, using relevant congenic strains for the role of RNO4 and 13 in the development of nephropathy in CDs. The current study posed several major challenges at its onset that we had to overcome in the course of the study. The first was anticipated high mortality rate in the diabetic animals. It was evident from the onset that it would take at least several months (equivalent to years in humans) for nephropathy attrib- uted to diabetes to develop in our rodent model. In fact, we had to maintain the animals on DD for at least 5 mo until clear signs of nephropathy evolved, findings that are consistent with our previous study of nephropathy in CDs (13) . Mortality among the parental CD strain fed DD approached 50% (13/26) within this time period, whereas mortality in SBN/y was only 5% (19/20). The high mortality we observed in CDs-DD was most likely due to the untreated diabetic state that the animals developed already after 1 mo, as the animals remained off any hypoglycemic treatment throughout the remaining 4 mo of the study. Unexpectedly, the 12% mortality in F1 (1/8) and 8% mortality in F2 (152/166) were much lower than in the parental CDs, the majority of the animals surviving the whole duration of the study. This occurred despite the fact that a significant proportion of F1 and F2 became equally diabetic as CDs. Survival of F1 and F2 suggests that their mixed genomic composition, resulting from the cross-breeding between CDs and SBN/y, somehow improved survival. The second challenge was prior knowledge that, because of random mixture of the genomes of the diabetes-prone CDs and nondiabetic SBN/y in F2, not all animals would develop the diabetic phenotype. Again unexpectedly, DD induced diabetes, as defined by the AUC of the OGTT, in Ͼ 2 ⁄3 of our F2 animals, suggesting a dominant pattern of inheritance. The third challenge was prior knowledge that not all animals that became diabetic would develop nephropathy. Studies in humans have shown that only ϳ¼-1 ⁄3 of diabetics go on to develop diabetic nephropathy (2) . Nonetheless, nearly ¾ of animals developed signs of nephropathy, far beyond the anticipated, also suggesting a dominant pattern of inheritance of the traits involved. A fourth challenge was in the traditional definition of diabetic nephropathy, which is usually identified first with the appearance of albuminuria/ proteinuria and only secondarily with a reduction in GFR. In the nonproteinuric type of nephropathy, as we previously described in CDs (13), the phenotypic expression of diabetic nephropathy consisted of reduced CrCl and increased plasma urea, without the development of proteinuria. In the current study, neither CDs nor SBN/y fed DD developed proteinuria; in CDs, however, a reduced CrCl and an increased plasma urea were observed, findings that are consistent with our previous report (13) . We were thus anticipating difficulty in identifying the animals with diabetic nephropathy, since we did not anticipate proteinuria as part of the phenotype in F1 or F2. As significant proteinuria did in fact develop in 2/7 of F1 and in 75% of F2 fed DD, we had to revise our definition of diabetic nephropathy in F1 and F2 to include proteinuria as well as one of the surrogates of the nephropathy that developed.
In summary, we have demonstrated in the current study that by mixing the genome of the nonproteinuric diabetic CDs strain with that of the nondiabetic nonproteinuric SBN/y strain, we unmasked the development of proteinuria in F2. Based on these findings, we speculate that in the diabetic CDs parental strain, the mechanisms that cause proteinuria are inhibited by a genomic factor, the nature of which yet remains to be determined. In F2, this inhibitory factor is somehow inactivated or absent, allowing the expression of proteinuria-related mechanisms to be activated and proteinuria to appear. These findings in our animal model raise the possibility that the difference between the proteinuric and nonproteinuric types of diabetic nephropathy in humans is also related to the absence of such an "inhibitory/protective" factor in the proteinuric variety. The importance of identifying the gene/s and or regulatory mechanism involved in unmasking proteinuria in CDs is potentially invaluable, as this may provide a clue to the prevention of proteinuria in diabetes in general and possibly in other renal diseases as well. This task of identifying this proteinuriainhibiting factor may be facilitated by the fact that we have already identified at least one genomic locus on RNO13 that harbors genes involved both in the development of diabetes and of the related nephropathy and proteinuria. Our next task is to identify the specific gene/s or regulatory element/s that this QTL incorporates and that modulate the expression of proteinuria. The downside is that even if we are able to identify the genes and mechanism involved in preventing proteinuria, these might not be sufficient to prevent the progression of kidney disease to end-stage renal disease. The natural course of NPDN, as shown in our animal model as well as in humans, is progression to kidney failure, irrespective of the level of proteinuria.
